Alteogen Inks Licensing Pact with Global Pharma Company to Develop, Commercialize Subcutaneous Biologic

Editor’s Take: This agreement opens Alteogen’s platform technology up to further global growth through strategic partnerships.

Alteogen entered an exclusive license agreement with a global pharmaceutical company for development and commercialization of a subcutaneous biologic product. The company, in an Aug. 5, 2026 press release, did not disclose the identity of the other party.

Alteogen, a biopharmaceutical company dealing in platform technologies, is using its Hybrozyme technology on this product. The product utilizes ALT-B4 (berahyaluronidase alfa), a recombinant human hyaluronidase developed via Hybrozyme.

Subcutaneous Biologic Versus Intravenous

ALT-B4, ideally, converts biologics typically given intravenously into more rapid subcutaneous forms. In more scientific terms, ALT-B4 depolymerizes hyaluronan in the extracellular matrix. This enables, again, rapid and efficient dispersion and absorption of co-administered therapies.

The Hybrozyme technology, meanwhile, not only enables subcutaneous administration, but is able to do so in large volumes.

“We will continue to accelerate growth of our platform technology through strategic global partnerships,” Alteogen CEO Tae-Yon Chun, PhD, said. Alteogen is based in South Korea and focuses on novel biologics including antibody-drug conjugates (ADCs), biobetters, and biosimilars.

What Alteogen Gets in the Deal

In this particular agreement, the other party acquires exclusive worldwide rights to develop and market the candidate. Alteogen stands to receive up to $365 million—this accounts for an upfront payment, plus development, regulatory, and sales goals.

“We are pleased to enter into this license agreement with a global leader,” Chun said. “[They have] a long-standing commitment to advancing innovative therapies for patients with serious unmet medical needs.”

Alteogen may additionally receive royalties based on net sales of the product covered in the agreement.

The Alteogen pipeline, beyond this ALT-B4-based candidate, includes clinical stage, long acting therapeutic proteins and next generation ADCs.